Company news
Amgen Inc. news in 2021
Amgen Inc.'s news releases, calls and decks from 2021, newest first.
Amgen Announces New Data Being Presented At ASH 2021
December 5, 2021
Amgen Announces 10% Increase In 2022 First Quarter Dividend
December 2, 2021
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
November 30, 2021
Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge
November 16, 2021
Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio
November 4, 2021
Amgen Reports Third Quarter 2021 Financial Results
November 1, 2021
Amgen Announces 2021 Fourth Quarter Dividend
October 20, 2021
Amgen Successfully Completes Acquisition Of Teneobio, Inc.
October 18, 2021
Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
October 6, 2021
Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment
October 3, 2021
Amgen Releases 8th Edition of Biosimilar Trends Report
September 21, 2021
Amgen Wins Patent Case on Otezla® (apremilast)
September 19, 2021
Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
September 12, 2021
Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21
September 7, 2021
Amgen Reports Second Quarter 2021 Financial Results
August 2, 2021
Amgen Announces 2021 Third Quarter Dividend
July 29, 2021
Amgen Appoints S. Omar Ishrak To Board Of Directors
July 28, 2021
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
July 26, 2021
Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge
July 13, 2021
Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
June 22, 2021
Amgen to Webcast Investor Meeting at ASCO 2021
May 31, 2021
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
May 9, 2021
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
May 4, 2021
Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study
April 27, 2021
Amgen Reports First Quarter 2021 Financial Results
April 26, 2021
Amgen Announces Webcast Of 2021 First Quarter Financial Results
April 21, 2021
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
April 18, 2021
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
April 15, 2021
Amgen to Acquire Rodeo Therapeutics Corporation
March 29, 2021
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
March 3, 2021
Amgen Announces 2021 Second Quarter Dividend
March 2, 2021
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
February 21, 2021
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results
February 1, 2021
Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
January 28, 2021
Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
January 27, 2021
Amgen To Achieve Carbon Neutrality By 2027
January 10, 2021
Calls in 2021
Decks in 2021
- Investor Presentation (October 2021)
Investor deck · 71 slides · Oct 4, 2021